Many patients combine medical weight loss programs with peptide therapy or hormone optimization for improved energy and metabolic health
If evoke/evoke+ were to confirm such an effect size, it would position semaglutide as a novel modality offering several potential advantages over anti-amyloid therapies such as Lillys donanemab, e.g., oral formulation, simpler diagnostics, likely no need for PET scan monitoring
You will need to complete the initial health questionnaire and physician consultation as a new patient
We stay at the forefront of medical advancements in weight management to ensure that you receive the highest standard of care
Abstract Introduction Novel glucagon-like peptide-1 (GLP-1) receptor agonist oral semaglutide has demonstrated greater improvements in glycated hemoglobin (HbA1c) and body weight versus oral medications empagliflozin and sitagliptin, and injectable GLP-1 analog liraglutide, in the PIONEER clinical trial program